...
首页> 外文期刊>Influenza and other respiratory viruses. >Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64years, 2007-2011
【24h】

Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64years, 2007-2011

机译:2007-2011年在20-64岁的澳大利亚成年人中,流感疫苗的中度有效性与循环菌株和疫苗株之间的匹配因变量而异

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Influenza vaccines are licensed annually based on immunogenicity studies. We used five sequential years of data to estimate influenza vaccine effectiveness (VE), the critical outcome in the field. Methods Between 2007 and 2011, we performed annual prospective test-negative design case-control studies among adults aged 20-64years recruited from sentinel general practices in the Australian state of Victoria. We used PCR-confirmed influenza as the endpoint to estimate influenza VE for all years. We compared annual VE estimates with the match between circulating and vaccine strains, determined by haemagglutination inhibition assays. Results The adjusted VE estimate for all years (excluding 2009) was 62% (95% CI 43, 75). By type and subtype, the point estimates of VE by year ranged between 31% for seasonal influenza A(H1N1) and 88% for influenza A(H1N1)pdm09. In 2007, when circulating strains were assessed as incompletely matched, the point estimate of the adjusted VE against all influenza was 58%. The point estimate was 59% in 2011 when all strains were assessed as well matched. Conclusion Trivalent inactivated vaccines provided moderate protection against laboratory-confirmed influenza in adults of working age, although VE estimates were sensitive to the model used. VE estimates correlated poorly with circulating strain match, as assessed by haemagglutination inhibition assays, suggesting a need for VE studies that incorporate antigenic characterization data.
机译:背景:流感疫苗每年根据免疫原性研究获得许可。我们使用了连续五年的数据来估计流感疫苗效力(VE),这是该领域的关键成果。方法在2007年至2011年之间,我们对澳大利亚维多利亚州前哨常规医疗机构招募的20-64岁成年人进行了年度前瞻性测试阴性设计病例对照研究。我们使用PCR确认的流感作为终点来估算所有年份的VE。我们将年度VE估计值与通过血凝抑制试验确定的循环株和疫苗株之间的匹配进行了比较。结果所有年份(不包括2009年)的调整后VE估算值为62%(95%CI 43、75)。按类型和亚型,季节性甲型流感(H1N1)的VE年度估计值介于31%和甲型流感(H1N1)pdm09的88%之间。在2007年,当循环菌株被评估为不完全匹配时,针对所有流感的调整后VE的点估计值为58%。当所有菌株都被评估为良好匹配时,2011年的得分估计为59%。结论三价灭活疫苗为工作年龄的成年人提供了针对实验室确诊流感的适度保护,尽管VE估计值对使用的模型敏感。通过血凝抑制试验评估,VE估计值与循环菌株匹配的相关性很差,这表明需要结合抗原表征数据进行VE研究。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号